Literature DB >> 2462522

Effects of the cholecystokinin receptor antagonist L-364,718 on experimental pancreatitis in mice.

M Silverman1, C Ilardi, S Bank, V Kranz, S Lendvai.   

Abstract

The effects of the cholecystokinin receptor antagonist L-364,718 was studied in a model of mild pancreatitis induced in mice by repeated injections of the secretagogue caerulein and in a lethal form of pancreatitis induced by feeding mice an ethionine-supplemented choline-deficient diet. L-364,718 prevented the caerulein-induced rise in serum amylase and pancreatic weight in a dose-dependent manner, the most effective dose being 0.1 mg/kg body wt. L-364,718 also prevented the caerulein-induced pancreatic inflammation as seen by light microscopy. L-364,718 offered no protective effects as determined by changes in serum amylase, pancreatic weight, histology, or mortality in the ethionine-supplemented choline-deficient diet model.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2462522     DOI: 10.1016/0016-5085(89)90779-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

1.  Cholecystokinin antagonists may have detrimental effects on acute pancreatitis.

Authors:  Isabel De Dios; Manuel A Manso
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

Review 2.  Clinical pharmacology and therapeutics.

Authors:  M J Kendall; R C Horton
Journal:  Postgrad Med J       Date:  1990-03       Impact factor: 2.401

Review 3.  Perspectives of CCK antagonists in pancreatic research and clinical use. Part I.

Authors:  L C Rovati
Journal:  Int J Pancreatol       Date:  1991-04

4.  Experimental pancreatitis is mediated by low-affinity cholecystokinin receptors that inhibit digestive enzyme secretion.

Authors:  A K Saluja; M Saluja; H Printz; A Zavertnik; A Sengupta; M L Steer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

5.  Effects of the bradykinin antagonist, HOE 140, in experimental acute pancreatitis.

Authors:  T Griesbacher; F Lembeck
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

6.  Influence of the CCK-antagonist loxiglumide on bile-induced experimental pancreatitis.

Authors:  U Leonhardt; F Seidensticker; M Fussek; F Stöckmann; W Creutzfeldt
Journal:  Int J Pancreatol       Date:  1991-09

7.  Clusterin and Pycr1 alterations associate with strain and model differences in susceptibility to experimental pancreatitis.

Authors:  Sapna Iyer; Min-Jung Park; David Moons; Raymond Kwan; Jian Liao; Li Liu; M Bishr Omary
Journal:  Biochem Biophys Res Commun       Date:  2016-12-07       Impact factor: 3.575

8.  Relationship of plasma CCK to acinar cell regeneration in acute pancreatitis as studied by proliferating cell nuclear antigen.

Authors:  J Sakagami; K Kataoka; A Ohta; T Nakajima
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

9.  Cholecystokinin antagonist L364,718 induces alterations in acinar cells that prevent improvement of acute pancreatitis induced by obstruction.

Authors:  Isabel De Dios; Aranzazu Uruñuela; Alberto Orfao; Manuel A Manso
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

10.  Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on cerulein-stimulated pancreatic exocrine secretion.

Authors:  N Watanabe; M Otsuki
Journal:  Int J Pancreatol       Date:  1993-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.